I'm glad you got back into HALO. My advice would be to stay in :-)
ADXS is a fine company and I appreciated the head's up when it was single digits.
I have been loosely following Northwest for years, as their technology is good. I haven't looked at the recent presentations (maybe I will) but it takes much more than good technology to get me to buy. This isn't the place to post too much about that. Keep sending ideas, though. I try to look at everything. If I feel like getting into the fray about Northwest, I'll head on over to that board.
I was worried about you, Sudn. Your trade has been a disaster since you posted itt On June first. ADXS fell a third. HALO continues to climb.
I do like ADXS. I don't like NWBO - no cash. Limited partnerships. Both have good technology. Meanwhile, HALO has it all; great tech, path to market for PEG clear as day, loads of cash, increasing revenues, great management.
"Early attempts by clinicians to target melanoma or renal tumors with attenuated forms of Salmonella typhimurium (ST) yielded mixed results. Although the bacteria successfully reached the tumors, they appeared to do little else. Diamond’s own studies found a similar failure to cause remission by the unmodified bacterium. This occurred, in part, because PDAC tumors use two tactics to evade treatments.
First, they secrete a thick physical barrier of hyaluronan, a sugary molecule that blocks drugs from reaching tumor cells. Second, they also produce copious amounts of a potent immunosuppressive molecule named indoleamine 2, 3-dioxygenase (IDO). IDO camouflages cancer cells and prevents the immune system from recognizing and killing the tumor.
In this new study, Diamond and his colleagues engineered ST to crack these tumor defenses. The researchers transformed bacteria to carry a piece of DNA that encodes a molecule capable of blocking IDO, known as small hairpin RNA-IDO, or simply shIDO. The modified bacteria, dubbed shIDO-ST, was combined with an enzyme (PEGPH20) that digests hyaluronan, provided to City of Hope for the study by Halozyme Therapeutics. When tumors were first pretreated with PEGPH20, the modified bacteria penetrated them much more effectively. This unique combination of bacteria and the enzyme induced a very potent anti-tumor response."
Also watched SC on PPV, though I live in NorCal. Had the Chicago tix already when they announced the local shows and decided, for once, too much might just be enough. I loved the intermission music and took the opportunity to learn more about Neal Casal. If you say Fade Away DT is the album to have, I'll get it.
Although I did see the boys a few times earlier (first at Wnterland in '78), like you, I didn't get hooked until those troubled years in the late 80s when I saw everything I could. You may be a familiar face.
Leaving for a music Fest in Grass Valley tomorrow. I play some guitar. It is one of several we do every year that brings together old friends. As you know, it is the late night jams that we live for. Have fun at yours.
Topical: I do my best to try to ignore the larger market but this indiscriminate rise in biotech doesn't seem sustainable in the short term. I am bracing for a correction but, who cares? Long term we are winners.
... Very long HALO, NVAX, ADXS. it's been quite a year:-)
Their Fisherman's Blues is a favorite. I agree, good stuff.
Lots of good friends, not seen in years, in Chicago.
well, they still have Mike Scott and Steve Wickham... that's two 'boys'
Saw all three GD Chicago shows and had a wonderful time - though Jerry definitely missed.
If you are NorCal based, make sure you check out Phil's place in San Rafael.
J&J Sales Hit by Biosimilars
Today's Financial Times
Regarding Remicade: "...the approval in Europe of a “biosimilar” version made by Celltrion, a South Korean group, had a dramatic impact on sales outside the US in the second quarter, which fell to $580m compared with $783m a year ago."
You do it in partnership with a generic company. Only HALO demands 50% of revenue.
Now you're thinking. Even the threat of that should spur those whose whose molecules are coming off patent to partner with us. I mentioned that possibility with Remicade right before J&J became our partner. I'll take full credit for getting that deal with HALO over the hump ;-).
But the real eye opener for me was the first deal for a new drug in development, whatever that sickle cell drug is called. When you factor in those, the possibilities are endless.
Less than two months ago ADXS priced a SPO at $19 per share. Many of those shares were hedged with options. Triple witching is tomorrow. This stock should resume its ascent soon after.
We don't need a royalty. We simply want the CAR-T company to pay for the trials if we supply the PEG.
A better analogy.
Someone offers to give you 10 million dollars to play one round of Russian roulette with one of six chambers loaded
HALO doesn't get her unless the inside view is clear.
Executive suite will be converting one of the men's restrooms...
Are there any guys left?
ADXS looks great.
Session Type: Oral Abstract Session
Track(s): Gastrointestinal (Noncolorectal) Cancer
10:00 AM - 10:12 AM
High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study.
Sunil R. Hingorani, MD, PhD
Fred Hutchinson Cancer Research Center"
Was it JP Morgan who surveyed the oncologists to find they would use PAG if the OS is greater than 10?
My guess, greater than 10.
Thank you, Rod.
You may be right. Before you take some off the table, consider opportunity cost if you timed it wrong.
Even with the recent run-up, I think it is hugely undervalued. HALO is just now selling for the highs it reached in early 2014. It is a 2.2 billion dollar company with plenty of cash, revenues ramping to nearly 100 million this year on the more 'boring' business that still seems to have 100% annual earnings growth, and a separate developing 'blockbuster' cancer product that now has much less safety and efficacy risk and is likely only a couple of years from market.
know when to hold 'em